Head-to-head comparative study: evaluating three panels for MSI-PCR testing in patients with colorectal and gastric cancer.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-09-19 DOI:10.1136/jcp-2023-209089

Xinhui Fu, Jinglin Huang, Xinjuan Fan, Chao Wang, Weihao Deng, Xiaoli Tan, Zhiting Chen, Yacheng Cai, Lin Hanjie, Liang Xu, Jiaxin Zou, Huanmiao Zhan, Shuhui Huang, Yongzhen Fang, Yan Huang

{"title":"Head-to-head comparative study: evaluating three panels for MSI-PCR testing in patients with colorectal and gastric cancer.","authors":"Xinhui Fu, Jinglin Huang, Xinjuan Fan, Chao Wang, Weihao Deng, Xiaoli Tan, Zhiting Chen, Yacheng Cai, Lin Hanjie, Liang Xu, Jiaxin Zou, Huanmiao Zhan, Shuhui Huang, Yongzhen Fang, Yan Huang","doi":"10.1136/jcp-2023-209089","DOIUrl":null,"url":null,"abstract":"Aims: Due to the lack of large clinical cohorts in the Chinese populations with colorectal cancer (CRC) and gastric cancer (GC), there is no consensus among the preferred panel for microsatellite instability (MSI)-PCR testing. This study aims to evaluate a more appropriate panel.Methods: We tested the MSI status of 2572 patients with CRC and GC using the NCI panel and 2 mononucleotide panels (5 and 6 mononucleotide panels). Immunohistochemistry (IHC) was employed to perform mismatch repair protein testing in 1976 samples.Results: We collected 2572 patients with CRC and GC. The National Cancer Institute (NCI) panel failed to detect 13 cases. Of the 2559 cases that received results from all three panels, 2544 showed consistent results. In the remaining 15 cases, 9 showed discrepancies between MSI-H and MSI-L, and 6 showed discrepancies between MSI-L and microsatellite stability (MSS). The misdiagnosis rate of MSI-L was significantly lower in two mononucleotide panels than in the NCI panel (12.5% vs 87.5%, p=0.010) in CRC. In patients with GC, only the NCI panel detected three MSI-L cases, while the results of the two mononucleotide panels were one MSI-H and two MSS. Based on their IHC results, the MSI-L misdiagnosis rate of the NCI panel was 33.3%. Furthermore, compared with two mononucleotide panels, the NCI panel had a much lower rate of all loci instability in CRC (90.8% and 90.3% vs 25.2%) and GC (89.5% and 89.5% vs 12.0%).Conclusion: In Chinese patients with CRC and GC, the five and six mononucleotide panels have advantages for detecting MSI over the NCI panel.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":" ","pages":"683-689"},"PeriodicalIF":4.6000,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11503178/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/jcp-2023-209089","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: Due to the lack of large clinical cohorts in the Chinese populations with colorectal cancer (CRC) and gastric cancer (GC), there is no consensus among the preferred panel for microsatellite instability (MSI)-PCR testing. This study aims to evaluate a more appropriate panel.

Methods: We tested the MSI status of 2572 patients with CRC and GC using the NCI panel and 2 mononucleotide panels (5 and 6 mononucleotide panels). Immunohistochemistry (IHC) was employed to perform mismatch repair protein testing in 1976 samples.

Results: We collected 2572 patients with CRC and GC. The National Cancer Institute (NCI) panel failed to detect 13 cases. Of the 2559 cases that received results from all three panels, 2544 showed consistent results. In the remaining 15 cases, 9 showed discrepancies between MSI-H and MSI-L, and 6 showed discrepancies between MSI-L and microsatellite stability (MSS). The misdiagnosis rate of MSI-L was significantly lower in two mononucleotide panels than in the NCI panel (12.5% vs 87.5%, p=0.010) in CRC. In patients with GC, only the NCI panel detected three MSI-L cases, while the results of the two mononucleotide panels were one MSI-H and two MSS. Based on their IHC results, the MSI-L misdiagnosis rate of the NCI panel was 33.3%. Furthermore, compared with two mononucleotide panels, the NCI panel had a much lower rate of all loci instability in CRC (90.8% and 90.3% vs 25.2%) and GC (89.5% and 89.5% vs 12.0%).

Conclusion: In Chinese patients with CRC and GC, the five and six mononucleotide panels have advantages for detecting MSI over the NCI panel.

查看原文本刊更多论文

头对头比较研究：评估用于结直肠癌和胃癌患者 MSI-PCR 检测的三种试剂盒。

目的：由于缺乏中国结直肠癌（CRC）和胃癌（GC）患者的大型临床队列，微卫星不稳定性（MSI）-PCR检测的首选面板尚未达成共识。本研究旨在评估一个更合适的样本库：方法：我们使用 NCI 面板和两个单核苷酸面板（5 和 6 单核苷酸面板）检测了 2572 例 CRC 和 GC 患者的 MSI 状态。采用免疫组织化学（IHC）方法对1976份样本中的错配修复蛋白进行检测：我们收集了 2572 例 CRC 和 GC 患者。美国国立癌症研究所（NCI）检测小组未能检测出 13 例病例。在获得所有三种检测结果的 2559 个病例中，有 2544 个病例的检测结果是一致的。在其余 15 个病例中，9 个病例的 MSI-H 和 MSI-L 存在差异，6 个病例的 MSI-L 和微卫星稳定性（MSS）存在差异。在 CRC 患者中，两个单核苷酸检验小组的 MSI-L 误诊率明显低于 NCI 检验小组（12.5% vs 87.5%，P=0.010）。在 GC 患者中，只有 NCI 面板检测出 3 例 MSI-L，而两个单核苷酸面板的结果是 1 例 MSI-H 和 2 例 MSS。根据他们的 IHC 结果，NCI 面板的 MSI-L 误诊率为 33.3%。此外，与两个单核苷酸面板相比，NCI面板在CRC（90.8%和90.3% vs 25.2%）和GC（89.5%和89.5% vs 12.0%）中的所有位点不稳定率要低得多：结论：在中国的 CRC 和 GC 患者中，5 个和 6 个单核苷酸基因组在检测 MSI 方面比 NCI 基因组更有优势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464